ORTHOPEDIATRICS CORP — fact timeline

ORTHOPEDIATRICS CORP shareholders approved Approval, on an advisory basis, of the appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2026 at the 2026-06-04 meeting.

“Approval, on an advisory basis, of the appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2026 The Company’s stockholders approved the appointment by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by voting as follows: For Against Abstain 20,479,183 154,131 47,235”

ORTHOPEDIATRICS CORP shareholders approved Approval of an amendment to the 2024 Incentive Award Plan to increase the number of shares authorized under the Plan by 2,050,000 shares, which would increase the total number of shares to 3,679,000 at the 2026-06-04 meeting.

“Approval, of an amendment to the 2024 Incentive Award Plan ("Plan") to increase the number of shares authorized under the Plan by 2,050,000 shares, which would increase the total number of shares to 3,679,000 The Company's stockholders approved the amendment to the 2024 Incentive Award Plan by voting as follows: For Against Abstain Broker Non-Votes 18,545,409 272,115 35,490 1,827,535”

ORTHOPEDIATRICS CORP shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers at the 2026-06-04 meeting.

“Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved the compensation of the Company's named executive officers by voting as follows: For Against Abstain Broker Non-Votes 15,953,457 2,859,793 39,764 1,827,535”

ORTHOPEDIATRICS CORP shareholders approved Election of Directors at the 2026-06-04 meeting.

“Election of Directors The nominees below were elected to serve as directors for a term that will last until the Company’s 2029 Annual Meeting of Stockholders or until his or her successor is duly elected and qualified. The number of votes cast for and withheld from each nominee and the number of broker non-votes with respect to each nominee were as follows: Name Votes For Votes Withheld Broker Non-Votes George S. M. Dyer 10,843,747 8,009,267 1,827,535 Kelly Fischer 18,535,024 317,990 1,827,535 David R. Pelizzon 18,056,773 796,241 1,827,535 Harald Ruf 18,077,260 775,754 1,827,535”

ORTHOPEDIATRICS CORP reported the first quarter ended March 31, 2026 results: revenue $59.4 million, net income Net loss for the first quarter of 2026 was $10.7 million, EPS $0.45 per basic and diluted share. Guidance raised.

“quarter ended March 31, 2026. First Quarter 2026 and Business Highlights • Helped a record of over 45,000 children in the first quarter of 2026 • Generated total revenue of $59.4 million for the first quarter of 2026, up 13% from $52.4 million in the first quarter of 2025; domestic revenue increased 11% and international revenue increased 22% in the quarter •”

ORTHOPEDIATRICS CORP amended term loan of not to exceed $20.0 million with Wilmington Trust, National Association at SOFR Interest Rate (with a floor of 3.25%) plus 6.50% maturing August 5, 2029.

“On March 31, 2026, OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers (collectively, the “Credit Parties”), entered into a First Amendment (the “Amendment”) to that certain Credit Agreement and Guaranty (the “Term Loan Agreement”) dated August 5, 2024, by and among the Credit Parties, any additional borrowers from time to time party thereto, any guarantors from time to time party thereto, one or more funds managed by Braidwell LP, as lenders, the other lenders from time to time party thereto, and Wilmington Trust, National Association, as agent. The Amendment provides the Company with incremental committed financing capacity by establishing a new delayed draw term loan facility in an aggregate principal amount not to exceed $20.0 million”

ORTHOPEDIATRICS CORP amended First Amendment with Braidwell LP valued at $20.0 million (effective 2026-03-31).

“On March 31, 2026, OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers (collectively, the “Credit Parties”), entered into a First Amendment (the “Amendment”) to that certain Credit Agreement and Guaranty (the “Term Loan Agreement”) dated August 5, 2024, by and among the Credit Parties, any additional borrowers from time to time party thereto, any guarantors from time to time party thereto, one or more funds managed by Braidwell LP, as lenders, the other lenders from time to time party thereto, and Wilmington Trust, National Association, as agent.”

ORTHOPEDIATRICS CORP reported the first quarter ended March 31, 2024 results: revenue $44.7 million, net income $7.8 million, EPS $0.34 per basic and diluted share. Guidance raised.

“Quarter 2024 and Business Highlights • Helped nearly 28,000 children in the first quarter of 2024, an increase of 47% from the first quarter 2023 • Generated total revenue of $44.7 million for the first quarter of 2024, up 41% from $31.6 million in first quarter 2023; domestic revenue increased 44% and international revenue increased 33% in the quarter • Grew”

ORTHOPEDIATRICS CORP reported full year 2024 results: revenue $197.0 million to $200.0 million. Guidance reaffirmed.

“Reiterated full year 2024 revenue guidance to be in a range of $197.0 million to $200.0 million”

ORTHOPEDIATRICS CORP reported the full year ended December 31, 2023 results: revenue $148.7 million. Guidance reaffirmed.

“Record full year 2023 revenue of $148.7 million increased 22% compared to prior year”

ORTHOPEDIATRICS CORP reported the fourth quarter ended December 31, 2023 results: revenue $37.6 million. Guidance reaffirmed.

“Generated total revenue of $37.6 million for fourth quarter 2023, up 21% from $31.0 million in fourth quarter 2022”

ORTHOPEDIATRICS CORP reported the fiscal year ending December 31, 2024 results: revenue $197 million to $200 million. Guidance initiated.

“OrthoPediatrics projects 2024 revenue to be in the range of $197 million to $200 million”

ORTHOPEDIATRICS CORP reported the full year ended December 31, 2023 results: revenue $148.7 million.

“Preliminary unaudited full year 2023 net revenue is expected to be $148.7 million”

ORTHOPEDIATRICS CORP reported the fourth quarter ended December 31, 2023 results: revenue $37.6 million.

“Preliminary unaudited fourth quarter 2023 net revenue is expected to be $37.6 million”

ORTHOPEDIATRICS CORP entered into Stock Purchase Agreement with Boston Brace International, Inc., the shareholders of Boston Brace (collectively, the Sellers) valued at $22 million in cash (effective 2024-01-05).

“On January 5, 2024, OrthoPediatrics Corp. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Boston Brace International, Inc., a Massachusetts corporation (“Boston Brace”), the shareholders of Boston Brace (collectively, the “Sellers”), and the Sellers’ representative named therein (the “Sellers’ Representative”), pursuant to which the Company acquired all of the issued and outstanding shares of capital stock of Boston Brace from the Sellers.”

ORTHOPEDIATRICS CORP incurred revolving credit of $50 million (the "Revolving Loan") with MidCap Funding IV Trust, as Agent; MidCap Financial Trust, as Term Loan Servicer; Lenders at the greater of (a) One Month Term SOFR plus 4.0% or (b) 6.50% maturing upon the earlier of December 1, 2028, or ....

“a revolving loan in an aggregate principal amount that will not exceed $50 million (the "Revolving Loan")”

ORTHOPEDIATRICS CORP incurred term loan of $30 million available in three tranches of $10 million each with MidCap Funding IV Trust, as Agent; MidCap Financial Trust, as Term Loan Servicer; Lenders at the greater of (a) One Month Term SOFR plus 6.50% or (b) 9.0% maturing the earlier of December 1, 2028, or ....

“the Lenders have provided to Borrowers a term loan in an aggregate principal amount that will not exceed $30 million available in three tranches of $10 million each subject to certain conditions (the "Term Loan")”

ORTHOPEDIATRICS CORP terminated Squadron Loan Agreement with Squadron Capital LLC (effective 2023-12-29).

“There was no indebtedness outstanding under the Squadron Loan Agreement and it was terminated in connection with the Credit Agreement.”

ORTHOPEDIATRICS CORP entered into Credit Agreement with MidCap Funding IV Trust, MidCap Financial Trust, and the Lenders valued at $80 million (effective 2023-12-29).

“On December 29, 2023, OrthoPediatrics Corp. (the “Company”) entered into a $80 million Credit, Security and Guaranty Agreement (the “Credit Agreement”)”

ORTHOPEDIATRICS CORP: Amended and restated Bylaws to adopt universal proxy card rules under Rule 14a-19 and enhance disclosure requirements for director nominations and stockholder proposals (effective 2023-11-02).

“On November 2, 2023, the Board of Directors (the “Board”) of OrthoPediatrics Corp. (the “Company”) approved and adopted, effective as of such date, amended and restated Bylaws (as so amended and restated, the “Bylaws”). The Bylaws amend and restate the Company’s prior bylaws in their entirety to, among other things, address the adoption by the U.S. Securities and Exchange Commission of new “universal proxy card” rules, as set forth in newly adopted Rule 14a-19 of the Exchange Act (“Rule 14a-19”) in order to ensure that, from a procedural and mechanical perspective, the Bylaws function properly in the case of a contested election using a new universal proxy card.”

ORTHOPEDIATRICS CORP updated its the third quarter ended September 30, 2023 guidance (reaffirmed).

“OrthoPediatrics Corp. issued a press release announcing its earnings for the quarter ended September 30, 2023”

ORTHOPEDIATRICS CORP reported the second quarter ended June 30, 2023 results: revenue $39.6 million, net income $2.9 million, EPS $0.13 per basic and diluted share. Guidance reaffirmed.

“OrthoPediatrics Corp. Reports Second Quarter 2023 Financial Results Record Setting Quarterly Revenue of $39.6 million”

ORTHOPEDIATRICS CORP shareholders approved Approval, on an advisory basis, of the appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2023 at the 2023-06-14 meeting.

“The Company’s stockholders approved the appointment by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 by voting as follows: For Against Abstain 21,268,308 21,630 137”

ORTHOPEDIATRICS CORP shareholders approved Selection, on an advisory basis, of the frequency of future advisory votes on executive compensation at the 2023-06-14 meeting.

“As reflected below, a majority of the votes cast advised that the vote on executive compensation should occur every year.”

ORTHOPEDIATRICS CORP shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers at the 2023-06-14 meeting.

“The Company's stockholders approved the compensation of the Company's named executive officers by voting as follows: For Against Abstain Broker Non-Votes 19,169,777 1,077,595 60,927 981,776”

ORTHOPEDIATRICS CORP shareholders approved Election of Directors at the 2023-06-14 meeting.

“The nominees below were elected to serve as directors for a term that will last until the Company’s 2026 Annual Meeting of Stockholders or until his successor is duly elected and qualified.”

ORTHOPEDIATRICS CORP completed an acquisition involving Kevin Unger and DINZE LLC for approximately $15.2 million (closed 2023-05-01).

“revenue contributions from the platform in 2023. Under the terms of the Purchase Agreement, the Sellers will be paid consideration in the aggregate amount of approximately $15.2 million, payable in the following manner: (i) cash in the aggregate amount of $3.0 million, on the transaction closing date (the “Closing Date”); (ii) 43,751 unregistered shares of the”

ORTHOPEDIATRICS CORP entered into Membership Interest Purchase Agreement with Kevin Unger and DINZE LLC valued at approximately $15.2 million (effective 2023-05-01).

“On May 1, 2023, OrthoPediatrics Corp. (the “Company”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Kevin Unger and DINZE LLC, an Ohio limited liability company (collectively, the “Sellers”), and the sole member of DINZE LLC, providing for the purchase by the Company of all of the issued and outstanding membership interest of Medtech Concepts, LLC”

ORTHOPEDIATRICS CORP reported the first quarter ended March 31, 2023 results: revenue $31.6 million, net income $6.8 million, EPS $0.30 per basic and diluted share. Guidance raised.

“Total revenue for the first quarter of 2023 was $31.6 million, a 35% increase compared to $23.4 million for the same period last year. The increase in revenue in the first quarter of 2023 includes $4.8 million of revenue contribution from MD Ortho and Pega Medical. U.S. revenue for the first quarter of 2023 was $23.8 million, a 31% increase compared to $18.2 million for the same period last year, representing 75% of total revenue. The increase in revenue in the first quarter of 2023 was driven primarily by organic growth in Trauma and Deformity and Scoliosis products as well as the addition of MD Ortho and Pega Medical. International revenue for the first quarter of 2023 was $7.8 million, a 49% increase compared to $5.2 million for the same period last year, representing 25% of total revenue. Growth in the quarter was primarily driven by the addition of MD Ortho and Pega Medical as well as increased procedure volumes. Trauma and Deformity revenue for the first quarter of 2023 was $23.4”

George S. M. Dyer, MD was appointed as Director at ORTHOPEDIATRICS CORP.

“Also effective April 28, 2023, the Board appointed George S. M. Dyer, MD, to fill the vacancy caused by Mr. Unger’s departure and to serve in the class of directors whose terms expire at the annual stockholder meeting in 2023.”

Kevin Unger resigned as Director at ORTHOPEDIATRICS CORP.

“On April 27, 2023, the Board accepted the resignation of Kevin Unger as a member of the Board, which became effective April 28, 2023.”

ORTHOPEDIATRICS CORP reported the fourth quarter and full year ended December 31, 2022 results: revenue $31.0 million. Guidance reaffirmed.

“bringing the total to more than 630,000 since the inception of OrthoPediatrics when combined with MD Orthopaedics ("MD Ortho") and Pega Medical • Generated total revenue of $31.0 million for fourth quarter 2022, up 25% from $24.8 million in fourth quarter 2021; domestic revenue increased 15% and international revenue increased 67% in 2022 • Generated record total”

ORTHOPEDIATRICS CORP updated its fourth quarter and full year ended December 31, 2022 guidance (initiated).

“On January 9, 2023, OrthoPediatrics Corp. (the "Company”) issued a press release announcing its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2022, providing management's projection of 2023 net revenue and providing a related business update.”

ORTHOPEDIATRICS CORP reported full year 2022 results: revenue $124 million to $125 million. Guidance lowered.

“For full year 2022, the Company now expects its full year revenue to be in the range of $124 million to $125 million, updated from its previous guidance range of $127 million to $130 million”

ORTHOPEDIATRICS CORP reported third quarter ended September 30, 2022 results: revenue $35.0 million, net income $18.5 million, EPS $0.87 per diluted share.

“Total revenue for the third quarter of 2022 was $35.0 million, a 39% increase compared to $25.1 million for the same period last year.”

Jimmy D. McDonald was appointed as Director at ORTHOPEDIATRICS CORP.

“effective October 18, 2022, the Board appointed Jimmy D. McDonald to fill the vacancy caused by Mr. Burns’ retirement to serve in the class of directors whose terms expire at the annual shareholder meeting in 2024.”

Stephen F. Burns retired as Director at ORTHOPEDIATRICS CORP.

“Effective October 18, 2022, Stephen F. Burns retired from the OrthoPediatrics Corp. (the “Company”) Board of Directors.”

David R. Bailey was appointed as Director at ORTHOPEDIATRICS CORP.

“The Board has appointed David R. Bailey, the Company’s President and Chief Executive Officer, to fill the vacancy caused by Mr. Berry’s retirement to serve in the Class of Directors whose terms expire at the annual shareholder meeting in 2024.”

Bernie Berry, III retired as Director at ORTHOPEDIATRICS CORP.

“Effective November 3, 2021, Bernie Berry, III has retired from the Company's Board of Directors after twelve years of service.”